BR0115071A - Usos de compostos de aminas heterocìclicas e de fenilazacicloalcano para tratamento de sìndrome de pernas inquietas (rls) - Google Patents

Usos de compostos de aminas heterocìclicas e de fenilazacicloalcano para tratamento de sìndrome de pernas inquietas (rls)

Info

Publication number
BR0115071A
BR0115071A BR0115071-5A BR0115071A BR0115071A BR 0115071 A BR0115071 A BR 0115071A BR 0115071 A BR0115071 A BR 0115071A BR 0115071 A BR0115071 A BR 0115071A
Authority
BR
Brazil
Prior art keywords
rls
treatment
phenylazacycloalkane
amine
restless leg
Prior art date
Application number
BR0115071-5A
Other languages
English (en)
Inventor
Sylvia Mcbrinn
Richard W Anderson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0115071A publication Critical patent/BR0115071A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"USOS DE COMPOSTOS DE AMINAS HETEROCìCLICAS E DE FENILAZACICLOALCANO PARA TRATAMENTO DE SìNDROME DE PERNAS INQUIETAS (RLS)". A invenção fornece usos de aminas heterocíclicas, e compostos de fenilazacicloalcano, e seus sais farmaceuticamente aceitáveis para preparação de medicamento para o tratamento da Síndrome de Pernas Inquietas (RLS).
BR0115071-5A 2000-10-31 2001-10-29 Usos de compostos de aminas heterocìclicas e de fenilazacicloalcano para tratamento de sìndrome de pernas inquietas (rls) BR0115071A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24466600P 2000-10-31 2000-10-31
PCT/US2001/027785 WO2002036123A2 (en) 2000-10-31 2001-10-29 New treatments for restless legs syndrome

Publications (1)

Publication Number Publication Date
BR0115071A true BR0115071A (pt) 2003-07-29

Family

ID=22923642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115071-5A BR0115071A (pt) 2000-10-31 2001-10-29 Usos de compostos de aminas heterocìclicas e de fenilazacicloalcano para tratamento de sìndrome de pernas inquietas (rls)

Country Status (18)

Country Link
US (2) US6602868B2 (pt)
EP (1) EP1330248A2 (pt)
JP (1) JP2004512367A (pt)
KR (1) KR20030042037A (pt)
CN (1) CN1606442A (pt)
AR (1) AR031152A1 (pt)
AU (1) AU2002211226A1 (pt)
BR (1) BR0115071A (pt)
CA (1) CA2421705A1 (pt)
EA (1) EA200300527A1 (pt)
IL (1) IL155591A0 (pt)
MX (1) MXPA03003912A (pt)
NO (1) NO20031923L (pt)
NZ (1) NZ525574A (pt)
PE (1) PE20020514A1 (pt)
PL (1) PL360904A1 (pt)
WO (1) WO2002036123A2 (pt)
ZA (1) ZA200301865B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
WO2004032853A2 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
AU2003267769A1 (en) * 2002-10-25 2004-05-13 Pharmacia & Upjohn Company Llc Use of heterocyclic amine-type compounds as neuroprotective agents
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
KR100905511B1 (ko) * 2005-01-28 2009-07-01 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
CN101263136A (zh) 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
WO2012039660A1 (en) * 2010-09-20 2012-03-29 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
HK1260897A1 (zh) 2015-08-21 2019-12-27 Portola Pharmaceuticals, Inc. 使用四氢异喹啉小分子来结合并调节pcsk9的蛋白活性的组合物和方法
EP3337788A4 (en) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP3565631B1 (en) 2017-01-05 2024-04-24 Noctrix Health, Inc. Restless leg syndrome or overactive nerve treatment
WO2021067751A1 (en) 2019-10-03 2021-04-08 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
EP4041376A1 (en) 2019-10-03 2022-08-17 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US12201783B1 (en) * 2023-09-05 2025-01-21 Steven F Pichette Use of blue-light filtering eyeglasses for treatment of restless legs syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
DK0641320T3 (da) 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PL343593A1 (en) 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
SE9802546D0 (sv) 1998-07-15 1998-07-15 Ross Nicholas Waters Medicinal product and method for treatment and prevention of dyskinesia
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
CA2405565A1 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona

Also Published As

Publication number Publication date
NO20031923D0 (no) 2003-04-29
US6716854B2 (en) 2004-04-06
MXPA03003912A (es) 2004-09-10
NO20031923L (no) 2003-06-27
IL155591A0 (en) 2003-11-23
ZA200301865B (en) 2004-06-25
PE20020514A1 (es) 2002-06-12
EP1330248A2 (en) 2003-07-30
EA200300527A1 (ru) 2003-08-28
JP2004512367A (ja) 2004-04-22
AR031152A1 (es) 2003-09-10
PL360904A1 (en) 2004-09-20
WO2002036123A3 (en) 2002-09-19
WO2002036123A2 (en) 2002-05-10
KR20030042037A (ko) 2003-05-27
US6602868B2 (en) 2003-08-05
CA2421705A1 (en) 2002-05-10
AU2002211226A1 (en) 2002-05-15
NZ525574A (en) 2004-12-24
US20030212065A1 (en) 2003-11-13
US20020107257A1 (en) 2002-08-08
CN1606442A (zh) 2005-04-13

Similar Documents

Publication Publication Date Title
AR031152A1 (es) Tratamientos nuevos para el sindrome de piernas inquietas
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
BR0113291A (pt) steres de aporfina e seu uso em terapia
BR0211289A (pt) Derivados de dolastatina 10
MY139506A (en) Hiv replication inhibitors
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
BR0309099A (pt) Composições farmacêuticas com base em anticolonérgicos e inibidores da p38 cinase
DK1267880T3 (da) Entecavir-formulering med lav dosis og anvendelse deraf
YU29102A (sh) Heteroalkilamino-supstituisani biciklični azotni heterocikli kao inhibitori p38 protein kinaze
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
TW200510339A (en) HIV replication inhibiting pyrimidines and triazines
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ATE463240T1 (de) Stabile zusammensetzung für eine orale dosis mit verlängerter freisetzung enthaltend pseudoephedrin and desloratadin
BRPI0408437A (pt) derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
MY117971A (en) Denaturants for sympathomimetic amine salts
DK1250328T3 (da) Dihydro-1,3,5-triazin-aminderivater og terapeutisk anvendelse deraf
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
UY27592A1 (es) Nuevo uso
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0101932D0 (sv) Pharmaceutical combinations
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
BRPI0415826A (pt) derivados de ceto-oxadiazol como inibidores de catepsina
BR0110357A (pt) Sais bicìclicos e n-aciclados de aminas imidazo - 3 e imidazo -5
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.